Domestic medicine started testing at teenagers with juvenile arthritis

Russian a preparation olokizumab will pass researches at children 12-17 lets juvenile idiopathic arthritis. According to the expert, clinical researches of similar level at children are conducted in the country for the first time. JOINT-STOCK COMPANY "R-FARM" reported about the beginning of the program of clinical trials of the preparation olokizumab at teenagers with the juvenile idiopathic arthritis, being shown polyarthritis. Juvenile idiopathic arthritis is considered the most widespread chronic rheumatologic disease at children and teenagers. Patients with this illness suffer progressing damage of joints, often...